{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Grade 5 Adverse Events"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"}],"title":"Grade 4 Adverse Events"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"Grade 3 Adverse Events"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.","groups":[{"description":"Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)"},{"description":"Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm B (Topotecan Hydrochloride, Carboplatin)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 7 months","title":"The Highest Grade Adverse Event Experienced","type":"SECONDARY","unitOfMeasure":"Participants"}